A Phase I Study of ZD6474 (Vandetanib) Concurrent With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2016
At a glance
- Drugs Vandetanib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 11 Jan 2011 Planned end date changed from 1 Apr 2012 to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 09 Dec 2010 Additional lead investigator identified as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned end date changed from 1 Jun 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.